Semaglutide
As of the edition of 20 October 2026, Semaglutide is a protein: marketed, first approved in 2017 (US); acts on GLP1R; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Protein
- Brand name
- Ozempic
- First approved
- 5 December 2017 (US)
- Approvals on record
- 55 in 5 regions
- Holder of the most recent approval
- RANBAXY FARMACĂUTICA LTDA; 9 holders in all
- Registered trials
- 469, 13 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Urinary and reproductive; Mental health; Heart and blood vessels; Pregnancy and women's health
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Novo Nordisk.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product93 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 93 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 103 | 57 | 38 | 3 |
| Phase 1 | 104 | 83 | 15 | 3 |
| Phase 2 | 80 | 32 | 43 | 2 |
| Phase 3 | 118 | 77 | 32 | 4 |
| Phase 4 | 64 | 16 | 38 | 1 |
| All trials | 469 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Originator, Applicant and Lead sponsor of trials | 2007 to now |